title: [A combined anti-emesis therapy of oral prednisolone and alprazolam for cisplatin-induced delayed emesis].
abstract: To evaluate the efficacy of a combined therapy of prednisolone and alprazolam for controlling cisplatin-induced delayed emesis, a study involving 14 non-small cell lung cancer patients receiving cisplatin (80 mg/m2) was conducted. Seven of these patients were given oral prednisolone at a dose of 30 mg/day for 5 days, then, 15 mg/day for 2 days, and with alprazolam at a dose 1.2 mg/day for 7 days. The other 7 patients were given an oral metoclopramide at a dose of 1 mg/kg/day for 5 days, and at 0.5 mg/kg/day for 2 days. All patients received 2 courses of chemotherapy and the same assigned regimen. Five of the 7 patients who had received prednisolone and alprazolam experienced no emesis, in contrast to only 1 patient who experienced no emesis from taking oral metoclopramide (p less than 0.05). Further, the duration of anorexia was shorter in those who received oral prednisolone with alprazolam. Thus, a combined therapy of oral prednisolone and alprazolam appears to be effective for controlling cisplatin-induced delayed emesis. Further evaluation and study, however, are necessary.
authors.affiliation: Dept. of Medicine, Japanese Red Cross Nagoya First Hospital.
authors.forename: A
authors.initials: A
authors.lastname: Watanabe
authors.forename: Y
authors.initials: Y
authors.lastname: Horio
authors.forename: H
authors.initials: H
authors.lastname: Minami
authors.forename: T
authors.initials: T
authors.lastname: Shibagaki
authors.forename: T
authors.initials: T
authors.lastname: Iwahara
authors.forename: S
authors.initials: S
authors.lastname: Sakai
authors.forename: K
authors.initials: K
authors.lastname: Shimokata
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000525:Alprazolam / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000009:adverse effects*; D004155:Diphenhydramine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D008787:Metoclopramide / Q000008:administration & dosage; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009325:Nausea / Q000517:prevention & control*; D011239:Prednisolone / Q000008:administration & dosage*; D014747:Vinblastine / Q000008:administration & dosage; D014839:Vomiting / Q000517:prevention & control*
chemical_list: D008937:Mitomycins; D016685:Mitomycin; D014747:Vinblastine; D004155:Diphenhydramine; D011239:Prednisolone; D008787:Metoclopramide; D002945:Cisplatin; D008775:Methylprednisolone; D000525:Alprazolam